HomeCompareGMND vs JNJ

GMND vs JNJ: Dividend Comparison 2026

GMND yields 1000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GMND wins by $4.7683925249533696e+36M in total portfolio value
10 years
GMND
GMND
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full GMND calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — GMND vs JNJ

📍 GMND pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGMNDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GMND + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GMND pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GMND
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, GMND beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GMND + JNJ for your $10,000?

GMND: 50%JNJ: 50%
100% JNJ50/50100% GMND
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GMND
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GMND buys
0
JNJ buys
0
No recent congressional trades found for GMND or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGMNDJNJ
Forward yield1000000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.7683925249533696e+36M$30.3K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.7683311610149396e+36M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GMND vs JNJ ($10,000, DRIP)

YearGMND PortfolioGMND Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,592$272.30+$100.00MGMND
2$934,786,450,701$934,679,439,252.34$11,289$357.73+$934786.44MGMND
3$8,165,787,108,578,292$8,164,786,887,076,042.00$12,123$472.89+$8165787108.57MGMND
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$13,141$629.86+$66665884190957.63MGMND
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$14,408$846.81+$508662171058048128.00MGMND
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$16,021$1,151.60+$3.62723524842849e+21MGMND
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$18,122$1,588.22+$2.417368115915061e+25MGMND
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$20,930$2,228.20+$1.5056740286145463e+29MGMND
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$24,792$3,191.91+$8.764771002818475e+32MGMND
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$4.7683925249533696e+36MGMND

GMND vs JNJ: Complete Analysis 2026

GMNDStock

Green Mountain Development Corp provides project development services for capital providers and technology operators; and distributes licensed products related to the energy, agricultural, and environmental sectors. The company assists clients with preliminary development work, including project due diligence, investor presentations, identification of project capital sources and technology vendors, and negotiation of a joint venture agreement between investors and the client. It also distributes Bio-Miracle microbial blends that are used for agricultural growth enhancement, composting acceleration, pond and lake water treatment, hydrocarbon reduction in soil and water, and animal and green waste treatment. The Bio-Miracle product lines include Remediline remediation products comprising SPILL KILL PRO, an oil spill cleanup product for soil and tank applications, and SIZZLE CLEAN, a microbe water based fizzing tablet for parts cleaning applications; Wasteline waste management products consisting of MANURE KING for cow/horse/pig manure control and SPARKLE CLEAN for septic and cesspool cleanup; and Bi-Agra agricultural products for increased plant health, size, and yield improvement, such as Bi-Agra-100, Bi-Agra-200, TOO TALL TOMATOES, and COMPOST PAL for backyard and commercial composting acceleration, as well as non-invasive dethatch applications. In addition, it focuses on the research, development, and production of a range of life science products. The company is based in Carlsbad, California.

Full GMND Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GMND vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GMND vs SCHDGMND vs JEPIGMND vs OGMND vs KOGMND vs MAINGMND vs ABBVGMND vs MRKGMND vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.